Clinical Trials Logo

Hemodialysis Catheter Infection clinical trials

View clinical trials related to Hemodialysis Catheter Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06093269 Recruiting - Clinical trials for Infection, Bacterial

Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)

CEFAZODIAL
Start date: November 20, 2023
Phase: Phase 4
Study type: Interventional

In chronic hemodialysis patients, bacteremia is most commonly caused by dialysis catheter infections. It is estimated that the vast majority (52-84%) of these infections are due to Gram-positive cocci, particularly Staphylococcus aureus (21-43%). Penicillin M (oxacillin and cloxacillin in France) is the reference beta-lactam for the treatment of invasive methicillin-sensitive S. aureus (MSSA) infections, but has not shown a prognostic benefit in large retrospective cohorts comparing penicillin M and cefazolin, at the expense of more frequent adverse events. Dosage in the chronic hemodialysis population is unclear because it is based on old studies.

NCT ID: NCT03539718 Recruiting - Clinical trials for Hemodialysis Catheter Infection

Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.

Start date: May 15, 2018
Phase: Phase 4
Study type: Interventional

To assess the efficacy of Taurolock-hep500™ as anticoagulant and antimicrobial catheter lock solution in comparison to unfractionated heparin as alock solution to improve performance of hemodialysis catheters and quality of hemodialysis .